Protective effects of resveratrol against streptozotocin-induced diabetes in rats by modulation of visfatin/sirtuin-1 pathway and glucose transporters

References

• Acquaviva R, Russo A, Campisi A, Sorrenti V, di Giacomo C, Barcellona ML, Avitabile M, Vanella A. 2002. Antioxidant activity and protective effect on DNA cleavage of resveratrol. J Food Sci 67:137–141
   Web of Science ®Google Scholar
• Adeghate E. 2008. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 15:1851–1862
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. 2004. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24:2783–2840
   PubMed Web of Science ®Google Scholar
• Akar F, Pektas MB, Tufan C, Soylemez S, Sepici A, Ulus AT, Gokalp B, et al. 2011. Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. Cardiovasc Drugs Ther 25:119–131
   PubMed Web of Science ®Google Scholar
• Akar F, Uludag O, Aydın A, Aytekin YA, Elbeg S, Tuzcu M, Sahin K. 2012. High-fructose corn syrup causes vascular dysfunction associated with metabolic disturbance in rats: protective effect of resveratrol. Food Chem Toxicol 50:2135–2141
   PubMed Web of Science ®Google Scholar
• Akiyama S, Katsumata SI, Suzuki K, Ishimi Y, Wu J, Uehara M. 2010. Dietary hesperidin exerts hypoglycemic and hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats. J Clin Biochem Nutr 46:87–92
   PubMed Web of Science ®Google Scholar
• Ates O, Cayli SR, Yucel N, Altinoz E, Kocak A, Durak MA, Turkoz Y, et al. 2007. Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci 14:256–260
   PubMed Web of Science ®Google Scholar
• Bagul PK, Middela H, Matapally S, Padiya R, Bastia T, Madhusudana K, Reddy BR, et al. 2012. Attenuation of insulin resistance: metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol Res 66:260–268
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 6:493–506
   Google Scholar
• Bayramoglu A, Bayramoglu G, Senturk H. 2013. Lycopene partially reverses symptoms of diabetes in rats with streptozotocin-induced diabetes. J Med Food 16:128–132
   PubMed Web of Science ®Google Scholar
• Bishnoi M, Bosgraaf CA, Abooj M, Zhong L, Premkumar LS. 2011. Streptozotocin-induced early thermal hyperalgesia is independent of glycemic state of rats: role of transient receptor potential vanilloid 1(TRPV1) and inflammatory mediators. Mol Pain 7:52–63
   PubMed Web of Science ®Google Scholar
• Bonnefont-Rousselot D. 2004. The role of antioxidant micronutrients in the prevention of diabetic complications. Treat Endocrinol 3:41–52
   PubMedGoogle Scholar
• Chang CC, Chang CY, Huang JP, Hung LM. 2012. Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chin J Physiol 55:192–201
   Google Scholar
• Chen H, Liu X, Chen H, Cao J, Zhang L, Hu X, Wang J. 2013. Role of SIRT1 and AMPK in mesenchymal stem cells differentiation. Ageing Res Rev 13:55–64
   Google Scholar
• Chi TC, Chen WP, Chi TL, Kuo TF, Lee SS, Cheng JT, Su MJ. 2007. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci 80:1713–1720
   PubMed Web of Science ®Google Scholar
• Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Inzucchi S, et al. 1999. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240–246
   PubMed Web of Science ®Google Scholar
• Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, Cohen HW, et al. 2012. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 12:1307–1312
   Google Scholar
• Cushman SW, Wardzala LJ. 1980. Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane. J Biol Chem 255:4758–4762
   PubMed Web of Science ®Google Scholar
• Deng JY, Hsieh PS, Huang JP, Lu LS, Hung LM. 2008. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes 57:1814–1823
   PubMed Web of Science ®Google Scholar
• Ding SY, Shen ZF, Chen YT, Sun SJ, Liu Q, Xie MZ. 2005. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacol Sin 26:575–580
   PubMed Web of Science ®Google Scholar
• Do GM, Jung UJ, Park HJ, Kwon EY, Jeon SM, McGregor RA, Choi MS. 2012. Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Mol Nutr Food Res 56:1282–1291
   PubMed Web of Science ®Google Scholar
• Eseberri I, Lasa A, Churruca I, Portillo MP. 2013. Resveratrol metabolites modify apdipokine expression and secretion in 3T3-L1 pre-adipocytes and manure adipocytes. PLoS One 8:e63918
   PubMed Web of Science ®Google Scholar
• Farombi EO, Shrotriya S, Na HK, Kim SH, Surh YJ. 2008. Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. Food Chem Toxicol 46:1279–1287
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, et al. 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426–430
   PubMed Web of Science ®Google Scholar
• Hirotani Y, Ikeda T, Yamamoto K, Kurokawa N. 2007. Effects of hachimi-jio-gan (ba-wei-di-huang-wan) on hyperglycemia in streptozotocin-induced diabetic rats. Biol Pharm Bull 30:1015–1020
   Google Scholar
• Imai S, Kiess W. 2009. Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Front Biosci 14:2983–2995
   PubMed Web of Science ®Google Scholar
• Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, et al. 1997. Cancer chemopreventive activity of resveratrol. A natural product derived from grapes. Science 275:218–220
   PubMed Web of Science ®Google Scholar
• Karatepe M. 2004. Simultaneous determination of ascorbic acid and free malondialdehyde in human serum by HPLC-UV. LC GC N Am 22:362–365
   Web of Science ®Google Scholar
• Kitada M, Kume S, Imaizumi N, Koya D. 2011. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 60:634–643
   PubMed Web of Science ®Google Scholar
• Knight CM, Gutierrez-Juarez R, Lam TK, Arrieta-Cruz I, Huang L, Schwartz G, Barzilai N, et al. 2011. Mediobasal hypothalamic SIRT1 is essential for resveratrol's effects on insulin action in rats. Diabetes 60:2691–2700
   Google Scholar
• Ku CR, Lee HJ, Kim SK, Lee EY, Lee MK, Lee EJ. 2012. Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic β-cell and the cleavage of poly (ADP-ribose) polymerase. Endocrinol J 59:103–109
   PubMed Web of Science ®Google Scholar
• Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, et al. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell 127:1109–1122
   PubMed Web of Science ®Google Scholar
• Martinez J, Moreno JJ. 2000. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 59:865–870
   PubMed Web of Science ®Google Scholar
• Marty N, Dallaporta M, Thorens B. 2007. Brain glucose sensing. counter regulation, and energy homeostasis. Physiology (Bethesda) 22:241–251
   PubMed Web of Science ®Google Scholar
• Melloul D, Marshak S, Cerasi E. 2002. Regulation of insulin gene transcription. Diabetologia 45:309–326
   PubMed Web of Science ®Google Scholar
• Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, et al. 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712–716
   PubMed Web of Science ®Google Scholar
• Mulakayala C, Babajan B, Madhusudana P, Anuradha CM, Rao RM, Nune RP, Manna SK, et al. 2013. Synthesis and evaluation of resveratrol derivatives as new chemical entities for cancer. J Mol Graph Model 4:43–54
   Google Scholar
• Negi G, Kumar A, Sharma SS. 2011. Melatonin modulates neuro-inflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades. J Pineal Res 50:124–131
   PubMed Web of Science ®Google Scholar
• Opara EC. 2002. Oxidative stress. micronutrients. diabetes mellitus and its complications. J R Soc Promot Health 122:28–34
   PubMedGoogle Scholar
• Orimo M, Minamino T, Miyauchi H, Tateno K, Okada S, Moriya J, Komuro I. 2009. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol 29:889–894
   PubMed Web of Science ®Google Scholar
• Oyedemi S, Koekemoer T, Bradley G, van de Venter M, Afolayan A. 2013. In vitro anti-hyperglycemia properties of the aqueous stem bark extract from Strychnos henningsii (Gilg). Int J Diabetes Dev Ctries 33:120–127
   Google Scholar
• Palsamy P, Subramanian S. 2008. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother 62:598–605
   PubMed Web of Science ®Google Scholar
• Palsamy P, Subramanian S. 2011. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta 1812:719–731
   PubMed Web of Science ®Google Scholar
• Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, et al. 2012. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675–690
   PubMed Web of Science ®Google Scholar
• Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, et al. 2007. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6:363–375
   PubMed Web of Science ®Google Scholar
• Roghani M, Baluchnejadmojarad T. 2010. Mechanisms underlying vascular effect of chronic resveratrol in streptozotocin-diabetic rats. Phytother Res 2:148–154
   Google Scholar
• Saddi-Rosa P, Viana de Oliveira CS, Crispim F, Giuffrida FM, de Lima VC, Vieira JG, Doria A, et al. 2013. Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects. Cardiovasc Diabetol 12:119–126
   Google Scholar
• Sahin K, Tuzcu M, Orhan C, Gencoglu H, Ulas M, Atalay M, Sahin N, et al. 2012. The effects of chromium picolinate and chromium histidinate administration on Nf-κβ and Nrf2/HO-1 pathway in the brain of diabetic rats. Biol Trace Elem Res 150:291–296
   Google Scholar
• Schmatz R, Mazzanti CM, Spanevello R, Stefanello N, Gutierres J, Maldonado PA, Corrêa M, et al. 2009a. Ectonucleotidase and acetylcholinesterase activities in synaptosomes from the cerebral cortex of streptozotocin-induced diabetic rats and treated with resveratrol. Brain Res Bull 80:371–376
   Google Scholar
• Schmatz R, Schetinger MR, Spanevello RM, Mazzanti CM, Stefanello N, Maldonado PA, Gutierres J, Corrêa Mde C, et al. 2009b. Effects of resveratrol on nucleotide degrading enzymes in streptozotocin-induced diabetic rats. Life Sci 84:345–350
   PubMed Web of Science ®Google Scholar
• Sellamuthu PS, Muniappan BP, Perumal SM, Kandasamy M. 2009. Antihyperglycemic effect of mangiferin in streptozotocin induced diabetic rats. J Health Sci 55:206–214
   Web of Science ®Google Scholar
• Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI, Cittadini A. 2001. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res 496:171–180
   PubMed Web of Science ®Google Scholar
• Sharma M, Gupta YK. 2002. Chronic treatment with transresveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 71:2489–2498
   PubMed Web of Science ®Google Scholar
• Sharma S, Anjaneyulu M, Kulkarni SK, Chopra K. 2006. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 76:69–75
   PubMed Web of Science ®Google Scholar
• Sies H. 1997. Oxidative stress: oxidants and antioxidants. Exp Physiol 82:291–295
   PubMed Web of Science ®Google Scholar
• Silan C. 2008. The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol Pharm Bull 31:897–902
   PubMed Web of Science ®Google Scholar
• Statistical Analysis System (SAS). 2002. User's guide statistics, version 9. Cary (NC): SAS Inst. Inc
   Google Scholar
• Stenbit AE, Tsao TS, Li J, Burcelin R, Geenen DL, Factor SM, Houseknecht K, et al. 1997. GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med 3:1096–1101
   PubMed Web of Science ®Google Scholar
• Su HC, Hung LM, Chen JK. 2006. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 290:1339–1346
   PubMed Web of Science ®Google Scholar
• Suzuki I, Kono T. 1980. Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site. Proc Natl Acad Sci USA 77:2542–2545
   PubMed Web of Science ®Google Scholar
• Tanaka T, Nabeshima Y. 2007. Nampt/PBEF/Visfatin: a new player in beta cell physiology and in metabolic diseases? Cell Metab 6:341–343
   Google Scholar
• Turan B, Tuncay E, Vassort G. 2012. Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies. J Bioenerg Biomembr 44:281–296
   PubMed Web of Science ®Google Scholar
• Vetterli L, Brun T, Giovannoni L, Bosco D, Maechler P. 2011. Resveratrol potentiates glucose-stimulated insulin secretion in INS-1E beta-cells and human islets through a SIRT1-dependent mechanism. J Biol Chem 286:6049–6060
   PubMed Web of Science ®Google Scholar
• Visioli F, Borsani L, Gali C. 2000. Diet and prevention of coronary heart disease: the potential role of phytochemicals. Cardiovasc Res 47:419–425
   PubMed Web of Science ®Google Scholar
• Wenzel E, Somoza V. 2005. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49:472–481
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053
   PubMed Web of Science ®Google Scholar
• Yar AS, Menevse S, Alp E. 2011. The effects of resveratrol on cyclooxygenase-1 and -2, nuclear factor kappa beta, matrix metalloproteinase-9, and sirtuin 1 mRNA expression in hearts of streptozotocin-induced diabetic rats. Genet Mol Res 10:2962–2975
   PubMed Web of Science ®Google Scholar
• Yoh K, Hirayama A, Ishizaki K, Yamada A, Takeuchi M, Yamagishi S, Morito N, et al. 2008. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 13:1159–1170
   PubMed Web of Science ®Google Scholar
• Zhu W, Chen S, Li Z, Zhao X, Li W, Sun Y, Zhang Z, et al. 2014. Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice. Nutr Metab (Lond) 12:11–35
   Google Scholar